RxDoctor Payments Data

Kelly Kynaston, DO

Infectious Disease · Redding, CANPI 1679852909

Payments from drug & device makers

$1,563in general payments, 2019–2025

Across 29 payments — averaging $53.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$404
  • Merck$370
  • AbbVie$234
  • Amgen$134
  • Boehringer Ingelheim$122
  • Pfizer$99
  • plus $201 from 7 others

What the payments were for

  • Food & beverage$1,52297%
  • Education$423%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,563 in reported general payments places this provider in the 65th percentile of 856 infectious disease providers in California.

See all infectious disease providers in California

Medicare billing

Part B allowed, 2024
$140,971
Medicare patients
380
Services billed
1,304

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala39$172,963
DovatoDolutegravir Sodium/Lamivudine12$34,381
TivicayDolutegravir Sodium13$28,841
DescovyEmtricitabine/Tenofov Alafenam13$28,136
VemlidyTenofovir Alafenamide11$16,872
Vancomycin Hcl63$15,856
Piperacillin-TazobactamPiperacillin Sodium/Tazobactam32$12,050
CeftriaxoneCeftriaxone Sodium36$8,344
Entecavir12$4,342
Cefazolin Sodium21$1,520
Doxycycline Hyclate47$1,087
Cephalexin22$340
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim21$194
Amoxicillin21$171
Ciprofloxacin Hcl12$161

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy, Vemlidy$404$217,97163 claims
Viiv Healthcare CompanyDovato, Tivicay$23$63,22225 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 856 infectious disease providers in California.

Other infectious disease in Redding

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →